Waldenstrom’s Macroglobulinemia pivotal study
Our clinical research study is enrolling now!
Consider joining the CLOVER-WaM pivotal study, a clinical research study for people with WM.
Participants in the CLOVER-WaM study will be given a new study drug, called CLR 131, to see if it may help manage their WM. The study drug is an intravenous infusion given up to 4 times over 3 months through an IV and each infusion takes about 20 minutes. This study drug is investigational, which means it has not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency.
The study drug is a targeted cytotoxic radiotherapeutic product, meaning it is designed to specifically kill cancer cells. Previous clinical research studies of the study drug have demonstrated response rates that are better than many currently approved drugs for third line therapy and beyond. The goal of the CLOVER-WaM study is to confirm the results from those studies so that more people may benefit from the study drug. You can find out more about those studies and the study drug on the Cellectar Biosciences website.
Note: The study drug, CLR 131, is an investigational study drug. An investigational study drug is one that has not been approved by the US Food and Drug Administration (FDA) or any other regulatory agency.